Bret Hafen
Psychiatric/Mental Health · Layton, UTNPI 1982060828
Payments from drug & device makers
Across 1,340 payments — averaging $284.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$203K
- AbbVie$76K
- Alkermes, Inc.$38K
- Johnson & Johnson$30K
- Otsuka America Pharmaceutical, Inc.$21K
- E.r. Squibb & Sons, L.L.C.$8K
- plus $6K from 16 others
What the payments were for
- Consulting fees$15,9254%
- Speaking & faculty fees$290,64476%
- Travel & lodging$51,84314%
- Food & beverage$22,4356%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 529 | $203,258 |
| AbbVie | 285 | $76,288 |
| Alkermes, Inc. | 120 | $37,509 |
| Johnson & Johnson | 90 | $30,069 |
| Otsuka America Pharmaceutical, Inc. | 87 | $20,506 |
| E.r. Squibb & Sons, L.L.C. | 28 | $7,732 |
| Janssen Scientific Affairs, LLC | 6 | $1,756 |
| Sunovion Pharmaceuticals Inc. | 88 | $1,207 |
| Vanda Pharmaceuticals Inc. | 27 | $578 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $405 |
| Neurocrine Biosciences, Inc. | 12 | $333 |
| Indivior Inc. | 15 | $318 |
| Lundbeck LLC | 12 | $232 |
| Axsome Therapeutics, Inc. | 11 | $206 |
| Braeburn Inc. | 6 | $196 |
| Teva Pharmaceuticals USA, Inc. | 5 | $82 |
| Neuronetics, Inc. | 4 | $80 |
| Eisai Inc. | 1 | $65 |
| Ironshore Pharmaceuticals Inc. | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Noven Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$196,170
- LYBALVI$131,006
- VRAYLAR$70,567
- INVEGA SUSTENNA$29,653
- INVEGA TRINZA$28,852
- ABILIFY ASIMTUFII$13,381
- ABILIFY MAINTENA$13,263
- REXULTI$5,854
- VIVITROL$2,597
- COBENFY$1,497
- INVEGA$1,125
- SPRAVATO$514
- ARISTADA$499
- Fanapt$125
- BRIXADI$125
- Auvelity$122
- INGREZZA$113
How this compares
$380,936 in reported general payments places this provider in the 95th percentile of 393 psychiatric/mental health providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 79 | $238,597 |
| Invega TrinzaPaliperidone Palmitate | 21 | $193,398 |
| Abilify MaintenaAripiprazole | 30 | $81,715 |
| VraylarCariprazine Hcl | 21 | $39,434 |
| CaplytaLumateperone Tosylate | 15 | $34,939 |
| VivitrolNaltrexone Microspheres | 14 | $22,187 |
| Lurasidone Hcl | 35 | $10,529 |
| Paliperidone ErPaliperidone | 13 | $6,788 |
| BelsomraSuvorexant | 14 | $6,310 |
| Lisdexamfetamine Dimesylate | 28 | $5,348 |
| DayvigoLemborexant | 11 | $3,739 |
| Clozapine | 88 | $3,475 |
| Quetiapine Fumarate | 96 | $2,970 |
| Lamotrigine | 130 | $2,591 |
| Ramelteon | 25 | $2,134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $30,069 | $431,995100 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $20,506 | $81,71530 claims |
| AbbVieVraylar | $76,288 | $39,43421 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $203,258 | $34,93915 claims |
| Alkermes, Inc.Vivitrol | $37,509 | $22,18714 claims |
| Eisai Inc.Dayvigo | $65 | $3,73911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 393 psychiatric/mental health providers in Utah.
Other psychiatric/mental health in Layton
- Colby JamesLayton$8K
- Craig FrancisLayton$7K
- Benjamin SaxeyLayton$7K
- Heather KrambuleLayton$6K
- Sherrie SmithLayton$4K
- Marie HurstLayton$4K
- Colin RileyLayton$3K
- Mitzy StewartLayton$3K
- Alberto SouzaSaint George$114K
- Anthony BrowningOrem$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.